Wednesday, 3 September 2008

OxyContin (4, 5-epoxy-14-hydroxy-3- methoxy-17-methylmorphinan-6-one): Purdue Pharma Strikes Licensing Deal with Mallinckrodt

Innovator Purdue Pharma and generics player Mallinckrodt have struck a deal that will allow Mallinckrodt to market and sell its cheaper version of the brand-name painkiller OxyContin (4, 5-epoxy-14-hydroxy-3- methoxy-17-methylmorphinan-6-one) for a licensing fee.
Innovator got approval on December 12, 1995 for marketing 15 10, 20, 30, 40, 80, 60 mg/tablet Extended release tablets

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker